DSTL Tender for Toxicology and Safety Pharmacology Studies
DSTL have a requirement for a contractor to carry out toxicity and safety pharmacology testing.
United Kingdom-Salisbury: Research and development services and related consultancy services
2019/S 077-183361
Contract notice
Services
Directive 2014/24/EU
Section I: Contracting authority
I.1)Name and addresses
Porton Down
Salisbury, Wiltshire
SP4 0JQ
United Kingdom
Telephone: +44 1980950000
E-mail: ratkinson@dstl.gov.uk
NUTS code: UK
I.3)Communication
I.4)Type of the contracting authority
I.5)Main activity
Section II: Object
II.1.1)Title:
Toxicology and Safety Pharmacology Studies
II.1.2)Main CPV code
II.1.3)Type of contract
II.1.4)Short description:
DSTL have a requirement for a contractor to carry out toxicity and safety pharmacology testing of an ovine polyclonal antitoxin in both rodents and rhesus macaques to identify the maximum tolerated dose administered by intravenous infusion that does not cause life-threatening pathology. The data obtained from this work will be used to support a clinical trial application and select the first in human dose. The testing should be undertaken in compliance with ICH guidelines.
II.1.6)Information about lots
II.2.3)Place of performance
II.2.4)Description of the procurement:
Toxicology and safety pharmacology studies.
II.2.5)Award criteria
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
II.2.10)Information about variants
II.2.11)Information about options
II.2.13)Information about European Union funds
II.2.14)Additional information
Section III: Legal, economic, financial and technical information
III.1.1)Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers
Section IV: Procedure
IV.1.1)Type of procedure
IV.1.8)Information about the Government Procurement Agreement (GPA)
IV.2.2)Time limit for receipt of tenders or requests to participate
IV.2.4)Languages in which tenders or requests to participate may be submitted:
Section VI: Complementary information
VI.1)Information about recurrence
VI.4.1)Review body
VI.4.3)Review procedure
VI.5)Date of dispatch of this notice: